Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurol Sci. 2009 Feb 1;277 Suppl 1:S33-6. doi: 10.1016/S0022-510X(09)70010-3.

Maximising therapeutic outcomes in patients failing on current therapy.

Author information

  • Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA. crcaon@med.wayne.edu

Abstract

The different immunomodulatory treatments available to patients with relapsing remitting multiple sclerosis are only partially effective. Since these treatments are most effective in the early relapsing stage of the disease, it is important to adjust therapy in a timely fashion in order to fall within the window of opportunity when maximal benefit can be gained from a second-line treatment. Consensus guidelines have been established to define a sub-optimal treatment response. Switching to another class of immunomodulatory therapy represents a logical treatment strategy in patients who fail to respond adequately to first line treatments. Several observational studied have now shown such a strategy to be beneficial. Disease control can be improved following switching in patients with persistent relapse activity on first-line treatment. In patients experiencing intolerable side-effects to first- line-treatment, tolerability can be improved by switching without loss of disease control. In particular, a switch between different classes of immunomodulatory treatments seems to be more beneficial than switching within the same class. Formal switching algorithms need to be developed in order to ensure that all patients who could benefit from such an approach are managed in a timely and optimal manner.

PMID:
19200864
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk